ALTIMMUNE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ALTIMMUNE, INC. (ALT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 1.46 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-12
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 655.29K shares, a 50.19% increase year-over-year.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 801.27K shares, a 1777.43% increase year-over-year.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 167.64K shares, a 414.67% increase year-over-year.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 148.11K shares, a 68.86% increase year-over-year.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 794.74K shares, a 108.54% increase from fiscal 2024.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 381.11K shares, a 399.52% increase from fiscal 2023.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 76.30K shares, a 74.52% decline from fiscal 2022.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 299.39K shares, a 39.29% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 655.29K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 1.46M shares 10-Q · filed 2026-08-12 | 1.62M shares derived: sum of 3 quarters · filed 2026-08-12 | 1.77M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 801.27K shares 10-Q · filed 2026-05-13 | 968.91K shares derived: sum of 2 quarters · filed 2026-05-13 | 1.12M shares derived: sum of 3 quarters · filed 2026-05-13 | 1.55M shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 167.64K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | 315.75K shares derived: sum of 2 quarters · filed 2026-03-06 | 752.06K shares derived: sum of 3 quarters · filed 2026-03-06 | 794.74K shares 10-K · filed 2026-03-06 |
| 2025-09-30 | 148.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 584.42K shares derived: sum of 2 quarters · filed 2025-11-06 | 627.10K shares 10-Q · filed 2025-11-06 | 659.67K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 436.32K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 479.00K shares 10-Q · filed 2025-08-12 | 511.57K shares derived: sum of 3 quarters · filed 2025-08-12 | 599.27K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 42.68K shares 10-Q · filed 2025-05-13 | 75.25K shares derived: sum of 2 quarters · filed 2025-05-13 | 162.96K shares derived: sum of 3 quarters · filed 2025-05-13 | 355.57K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 32.57K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 120.28K shares derived: sum of 2 quarters · filed 2025-02-27 | 312.89K shares derived: sum of 3 quarters · filed 2025-02-27 | 381.11K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 87.71K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 280.32K shares derived: sum of 2 quarters · filed 2024-11-12 | 348.53K shares 10-Q · filed 2024-11-12 | |
| 2024-06-30 | 192.61K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 260.82K shares 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 68.21K shares 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | 76.30K shares 10-K · filed 2024-03-27 | |||
| 2022-12-31 | 299.39K shares 10-K · filed 2023-02-28 | |||
| 2021-12-31 | 214.94K shares 10-K · filed 2022-03-15 | |||
| 2020-12-31 | 7.45K shares 10-K · filed 2021-02-25 | |||
| 2019-12-31 | 105.10K shares 10-K · filed 2020-03-27 | |||
| 2018-12-31 | 37.42K shares 10-K · filed 2019-04-01 | |||
| 2017-12-31 | 110.86K shares 10-K · filed 2018-04-02 | |||
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | 0.00 shares derived: sum of 2 quarters · filed 2016-11-04 | 186.96K shares 10-Q · filed 2016-11-04 | |
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | 186.96K shares 10-Q · filed 2016-08-04 | ||
| 2016-03-31 | 186.96K shares 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |